[논문]우리나라 소아에게 황열예방 백신을 투여 후 발생한 부작용에 대한 고찰

이재요; 김태희; 박향미; 신혜정; 김경은; 이상택; 김재윤

doi:10.14776/kjpid.2009.16.1.54

우리나라 소아에게 황열예방 백신을 투여 후 발생한 부작용에 대한 고찰
Adverse Events Following Yellow Fever Vaccination in Korean Children 원문보기

소아감염 = Korean journal of pediatric infectious diseases, v.16 no.1, 2009년, pp.54 - 60

이재요 (국립의료원 소아청소년과) , 김태희 (국립의료원 소아청소년과) , 박향미 (국립의료원 소아청소년과) , 신혜정 (국립의료원 소아청소년과) , 김경은 (국립의료원 소아청소년과) , 이상택 (국립의료원 소아청소년과) , 김재윤 (국립의료원 소아청소년과)

초록
AI-Helper

목 적: 황열은 모기에 의해 전염되는 급성 바이러스 출혈열로 중부아프리카와 열대 남아메리카에서 주로 발생한다. 이 연구는 황열 백신을 접종한 소아 및 청소년 여행객에게 이상반응에 대한 임상적 고찰을 시행하여 백신의 안전성 및 이상반응에 대한 정보를 제공하고자 시행하였다. 방 법: 이 연구에서는 2007년 4월 1일-2008년 6월 30일까지 국립의료원 해외여행클리닉을 방문한 소아 및 청소년 125명을 대상으로 하였다. 황열백신 투여 이후 6회의 전화면담을 통해 백신투여와 이상반응과의 관련성에 대하여 평가하였다. 결 과: 황열백신을 투여한 11개월에서 19세 사이의 소아 및 청소년 125명 중 이상반응의 발생은 31명(24.8 %)이었다. 증상으로는 주사부위의 통증(8.8%)이 가장 많았고 뒤를 이어 부종(6.4%), 발적(5.6%), 발열(4.0%), 두통(4.0%)순서였다. 대부분의 이상반응은 백신 투여 후 7일 이내에 발생했으며 성별 및 연령과 이상반응간의 유의한 차이가 없었다. 증상을 호소한 모두 자연적으로 혹은 보존적인 치료에 증상이 호전되었다. 결 론: 이 연구에서 황열백신은 우리나라 소아나 청소년에게 심각한 이상반응 없이 널리 사용될 수 있음을 보여주었다. 그러나 심각한 부작용의 원인이나 위험요소에 대한 연구는 지속적으로 필요할 것이다.

Abstract ▼ AI-Helper

Purpose : Yellow fever, a mosquito-borne viral hemorrhagic fever, is one of the most lethal diseases. Recently there have been an increasing number of Korean children who have travelled to yellow fever endemic zones and were administered yellow fever vaccine (YFV). Therefore, we carried out this study to provide child travelers with safety information of YFV. Methods : This study was conducted at the International Clinic of National Medical Center in Seoul between April 2007 and June 2008 for the evaluation of adverse events of YFV. One hundred twenty-five children received YFV (17-DD) and were prospectively monitored for adverse events through telephone interviews on day 3, 6, 9, 16, 23 and 30 after vaccination. Results : Adverse events were observed in 31 (24.8%) of 125 child travelers who received the YFV. The mean age was 12.5${\pm}$5.0 years. Sixty-six of the child travelers (52.8%) were males. The common adverse events were pain in 11 (8.8%), swelling in 8 (6.4%) and redness in 7 children (5.6%) at the injection site. The systemic adverse events included mild fever in 5 (4.0%), headache in 5 (4.0%), cough in 4 (3.2%), abdominal pain in 3 (2.4%), and vomiting in 2 children (1.6%). Most of the adverse events were detected within 7 days of administration and there were no differences in adverse events by gender or age. All travelers who had complained of symptoms improved spontaneously or following symptomatic treatment. Conclusion : This study showed that YFV is well-tolerated and there were no reports of severe adverse events. Studies are ongoing to clarify the cause and risk factors for rare adverse events.

주제어

AI 본문요약
AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

2). Therefore, we carried out this study to provide children traveling to YF endemic zones with safety information of YFV through a prospective re-search for adverse events after YF vaccination.

제안 방법

This study was explained to the parents and informed consent was obtained from the parents. They were examined by six telephone interviews on day 3, 6, 9, 16, 23 and 30 after vaccination.

대상 데이터

From April 1, 2007 to June 30, 2008, 125 healthy children aged from 11 months to 19 years who visited the International Clinic at the National Medical Center and had plans to visit to yellow fever endemic areas, were chosen as study subjects. This study was explained to the parents and informed consent was obtained from the parents.
0 years (Table 2). The destination was Africa and South America (110:15) (Table 3).
The vaccine for the study was manufactured by Bio- Manguinhos (YFV-17DD), Brazil (Table 1)5, 6). A single dose of 0.
The vaccine for the study was manufactured by Bio- Manguinhos (YFV-17DD). This company is WHO-prequalified manufacturer linked to the Brazilian Ministry of Health supplies YFV for Brazilian and other countries in South America and Africa20).

데이터처리

For this study the statistical data processing was done with SPSS (ver.12.0K), the frequency analysis was used for the basic data of examples, and the difference of each variable was compared using Fisher's exact test or chi-square verification. In all cases, the differences were considered significant when the probabilities of equality, P-value, were <0.

성능/효과

In conclusion, YFV appears to be safe in Korean children, but the additional reaearch on adverse events and effectiveness will be necessary.

참고문헌 (35)

Thompson MJ. Immunizations for international travel. Prim Care 2002;29:787-814.

상세보기
Mutebi JP, Barrett AD. The epidemiology of yellow fever in Africa. Microbes Infect 2002;4:1459-68.

상세보기
Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34:1369-78.

상세보기
Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001;358:98-104.

상세보기
Post PR, de Carvalho R, da Silva Freire M, Galler R. The early use of yellow fever virus strain 17D for vaccine production in Brazil-a Review. Memorias Instituto Oswaldo Cruz 2001;96:849-57.

상세보기
Filippis AM, Nogueira RM, Jabor AV, Schatzmayr HG, Oliveira JC, Dinis SC, et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 2004;22:1073-8.

상세보기
Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, Paul A, editors. Vaccines. 5th ed. Philadelphia: Elsevier, Inc, 2008:959-1055.
Sood SK. Immunization for children traveling abroad. Pediatr Clin North Am 2000;47:435-48.

상세보기
Monath TP. Yellow fever: an update. Lancet Infect Dis 2001;1:11-20.

상세보기
Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007;44:850-6.

상세보기
Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007;52:209-29.

상세보기
Centron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002;51: 1-11.
Spira A. Yellow fever vaccine as a vehicle to better travel medicine. J Travel Med 2005;12:303-5.

상세보기
Fitzner J, Coulibaly D, Kouadio DE, Yavo JC, Loukou YG, Koudou PO, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 2004;23:156-62.

상세보기
Jong EC, Kaplan KM, Eves KA, Taddeo CA, Lakkis HD, Kuter BJ. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. J Travel Med 2002;9:66-70.

상세보기
CDC. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR Morb Mortal Wkly Rep 2001;50: 643-5.
Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005;18:387-94.

상세보기
Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999;60:1045-50.

상세보기
Collaborative Group for Studies with Yellow Fever Vaccine. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children : Implications for the Brazilian National Immunization Program. Vaccine 2007;25:3118-23.

상세보기
Martins MA, Silva ML, Marciano AP, Peruhype- Magalhes V, Eloi-Santos SM, Ribeiro GL, et al. Activation/ modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse events following immunization? Clin Exp Immunol 2007;148:90-100.

상세보기
Camacho LA, Freire Mda S, Leal Mda L, Aguiar SG, Nascimento JP, Iguchi T, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004;38:671-8.

상세보기
Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001;358:91-7.

상세보기
Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-2.

상세보기
Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004;22:2103-5.

상세보기
Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005;23:3256-63.

상세보기
CDC. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002;51:989-93.
Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005;19: 151-68.

상세보기
Arya SC. Yellow fever vaccine safety: a reality or a myth? Vaccine 2002;20:3627-8.

상세보기
Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1:207-14.
Engel AR, Vasconcelos PF, McArthur MA, Barrett AD. Charaterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006;24:2803-9.

상세보기
McGovern LM, Boyce TG, Fischer PR. Congenital infections associated with international travel during pregnancy. J Travel Med 2007;14:117-28.

상세보기
Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ 2001;79:1056-9.

상세보기
Rabello A, Orsini M, Disch J, Marcial T, Leal Md Mda L, Freire Md Mda S, et al. Low frequency of side effects following an incidental 25 times concentrated does of yellow fever vaccine. Rev Soc Bras Med Trop 2002; 35:177-80.

상세보기
Choudri Y, Walop W. Review of adverse events reported following use of fever vaccine-Canada, 1987-2000. Can Commun Dis Rep 2002;28:9-15.

상세보기
Robertson S. Yellow fever: the immunological basis for immunization. Document WHO/EPI/GEN/93. 181993.

저자의 다른 논문 :

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증